Compare Figs Inc (FIGS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

FIGS stock trades at $15.78, up 12.23% over the past day, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while recent earnings beats and raised 2026 guidance highlight fundamental strength. Revenue growth accelerated to 28.8% in Q2 2026, with international sales surging 67%, and the company maintains a high gross margin of 68.91%.

The investment outlook is positive, with a consensus price target of $18.00 implying 14% upside. However, risks include a rich valuation (P/E of 45.39) and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, with 60% recommending buy, but investors should monitor margin pressures and competitive dynamics.

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.